MRSN · As filed with the SEC
Mersana Therapeutics cash flow statement, by fiscal year
The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Segment and consolidated net loss | (69,192) | (171,670) | (204,212) | (170,060) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 1,628 | 1,517 | 927 | 855 |
| Net amortization of premiums and discounts on marketable securities | (3,917) | (4,569) | (1,462) | 0 |
| Stock-based compensation | 16,458 | 21,136 | 21,522 | 18,409 |
| Non-cash operating lease expense | 3,116 | 2,780 | — | — |
| Other non-cash items | 305 | 687 | 763 | 723 |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 0 | 30,000 | (30,000) | 0 |
| Prepaid expenses and other current assets | 2,689 | 3,534 | 3,863 | (2,734) |
| Other assets | (500) | 0 | 0 | (718) |
| Accounts payable | (2,857) | (6,080) | 947 | 483 |
| Accrued expenses | (2,934) | (20,935) | 13,594 | 12,570 |
| Operating lease right-of-use assets | — | — | 2,777 | 1,829 |
| Operating lease liabilities | (3,254) | (3,143) | (2,539) | (1,827) |
| Deferred revenue | (23,882) | (22,139) | 143,709 | (43) |
| Other liabilities | 0 | 0 | 748 | 525 |
| Net cash used in operating activities | (82,340) | (168,882) | (49,363) | (139,988) |
| Cash flows from investing activities | ||||
| Maturities of marketable securities | 145,000 | 277,970 | 97,000 | 0 |
| Purchase of marketable securities | (133,431) | (155,919) | (247,519) | 0 |
| Purchase of property and equipment | (132) | (2,168) | (2,197) | (648) |
| Net cash provided by (used in) investing activities | 11,437 | 119,883 | (152,716) | (648) |
| Cash flows from financing activities | ||||
| Public Stock Offering | — | — | 0 | 0 |
| At Market Equity Offering Program | 5,780 | 93,539 | 150,893 | 43,087 |
| Proceeds from exercise of stock options | 56 | 427 | 1,331 | 1,837 |
| Proceeds from purchases of common stock under ESPP | 486 | 1,121 | 1,065 | 640 |
| Payment of employee tax obligations related to vesting of restricted stock units | — | 0 | 0 | (259) |
| Proceeds from issuance of debt, net of issuance costs | 0 | (150) | 0 | 24,042 |
| Repayment of debt | (2,083) | 0 | 0 | (5,486) |
| Payments under finance lease obligations | (147) | (262) | (272) | (215) |
| Net cash provided by financing activities | 4,092 | 94,675 | 153,017 | 63,646 |
| (Decrease) increase in cash, cash equivalents and restricted cash | (66,811) | 45,676 | (49,062) | (76,990) |
| Cash, cash equivalents and restricted cash, beginning of period | 175,039 | 129,363 | 178,425 | 255,415 |
| Cash, cash equivalents and restricted cash, end of period | 108,228 | 175,039 | 129,363 | 178,425 |
| Supplemental cash flow information: | ||||
| Cash paid for income taxes | 418 | — | — | — |
| Fair value of common stock retired in exchange for issuance of pre-funded warrants | 13,984 | — | — | 0 |
| Purchases of property and equipment in accounts payable and accrued expenses | 0 | 132 | 753 | 0 |
| Debt financing costs in accrued expenses | 0 | 0 | 150 | 0 |
| Common stock issuance costs in accounts payable and accrued expenses | 0 | 0 | 131 | — |
| Cash paid for interest | 3,467 | 3,380 | 2,463 | 429 |
| Right-of-use assets obtained in exchange for operating lease liabilities | 0 | 0 | 298 | 3,783 |
| Right-of-use assets obtained in exchange for financing lease liabilities | — | 0 | 0 | 609 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.